MoonLake Immunotherapeutics (MLTX) Non Operating Income (2021 - 2022)
MoonLake Immunotherapeutics (MLTX) posted quarterly Non Operating Income of $7774.0 for Q1 2022, down 56.36% year-over-year from $17815.0 in Q1 2021, and up 244.75% quarter-over-quarter from $2255.0 in Q4 2021.
Powered by 
Analysis
MoonLake Immunotherapeutics (MLTX) Non Operating Income (2021 - 2022) Analysis & Trends
MoonLake Immunotherapeutics' Non Operating Income history runs 2 years deep, the most recent figure standing at $7774.0 for Q1 2022.
- In Q1 2022, Non Operating Income fell 56.36% year-over-year to $7774.0; the TTM figure through Mar 2022 stood at $17650.0 (changed N/A YoY), while the FY2021 annual figure was $27691.0, up 85.63% from the prior year.
- Non Operating Income for Q1 2022 stood at $7774.0, up from $2255.0 in the prior quarter.
- The five-year high for Non Operating Income was $17815.0 in Q1 2021, with the low at $1481.0 in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -139.24 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -51.63 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | MoonLake Immunotherapeutics | 1.10 Bn | 565.05 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | 7,774.00 |
| Dec 31, 2021 | 2,255.00 |
| Sep 30, 2021 | 1,481.00 |
| Jun 30, 2021 | 6,140.00 |
| Mar 31, 2021 | 17,815.00 |